Document is current
Any future updates will be listed below
-
Authors
Shin, Jae Hoon https://orcid.org/0000-0001-5247-4345
Bozadjieva-Kramer, Nadejda
Seeley, Randy J. https://orcid.org/0000-0002-3721-5625
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01DK133140)
U.S. Department of Health & Human Services | National Institutes of Health (P30DK089503)
U.S. Department of Health & Human Services | National Institutes of Health (P01DK117821)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
National Research Foundation of Korea (2018R1A6A3A03011269)
- License Information
-
More Information
Article History
Received: 11 April 2023
Accepted: 1 May 2023
First Online: 1 August 2023
Competing interests
: RJS has received research support from Novo Nordisk, Fractyl, Astra Zeneca and Eli Lilly. RJS has served as a paid consultant for Novo Nordisk, Eli Lilly, Scohia, CinRx, Fractyl, Structure Therapeutics and Congruence Therapeutics. RJS has equity in Calibrate and Rewind. The other authors declare no competing interests.
